Group 1 - A new round of QDII quotas has been approved, leading to a relaxation of purchase limits for several QDII funds, with 79 funds having adjusted their limits as of July 8 [1][4][6] - QDII funds focused on Hong Kong innovative pharmaceuticals and new consumption have achieved over 50% returns, while those targeting US stocks have seen close to 10% returns [1][8] - The overall valuation of Hong Kong stocks remains low compared to US stocks, suggesting that QDII funds investing in Hong Kong may continue to outperform those investing in the US [1][8][9] Group 2 - Several fund companies, including E Fund and Huaan Fund, have announced adjustments to their large purchase limits for QDII funds, significantly increasing the daily purchase limits for various funds [2][3] - As of July 8, 393 out of 675 QDII funds are either suspended from large purchases or in a closed period, indicating a significant portion of the market is still facing purchase restrictions [7] - The recent approval of $30.8 billion in new QDII investment quotas has alleviated some of the foreign exchange constraints faced by fund companies, although structural shortages in quotas still exist [4][6][7] Group 3 - The performance of QDII funds has been strong, with the best-performing fund, focused on Hong Kong innovative pharmaceuticals, showing a net value increase of 86.48% [8] - The valuation of US stocks has reached historical highs, with the Nasdaq index PE at 42.06 and the S&P 500 PE at 27.88, indicating potential risks for US stock investments [8] - Hong Kong stocks, particularly in high dividend and innovative pharmaceutical sectors, are viewed as having good investment opportunities due to their lower valuations, with the Hang Seng Index PE at 10.64 [9]

上天天基金APP搜索【777】注册即可 领500元券包 ， 优选QDII基金10元起投！限量发放！先到先得！ 随着6月末国家外汇局新发放一批QDII额度，此前囿于额度从而限购、溢价的基金得以"解渴"，近期多只 QDII基金公告放宽限购额度，且部分场内ETF的溢价也有缓解之势。 作为QDII基金两大"去向"，港股与美股两大市场一直是投资焦点。半程行情落幕，港股QDII基金业绩大幅跑 赢美股相关产品，随着下半年行情开启，美股纳指、标普走出历史新高，港股当前估值仍然低于历史平均水 平，多家公募依旧旗帜鲜明地看好两大市场的投资前景。 多只QDII基金放宽限购额度 7月7日，易方达基金公告批量发布调整大额申购业务限制公告，调整旗下易方达标普医疗保健LOF、易方达信 息科技LOF、易方达生物科技LOF、易方达标普500LOF、易方达纳斯达克100ETF联接5只QDII的大额申购上 限。其中易方达纳斯达克100ETF联接单日申购上限从100元人民币调整至2000元，其余4只从100元调整至1000 元。 此外，近日华宝基金发布公告称，华宝致远混合型基金(QDII)将大额申购门槛由2万元调整为20万元，华宝纳 斯达克精选股票 ...

随着6月末国家外汇局新发放一批QDII额度，此前囿于额度从而限购、溢价的基金得以"解渴"，近期多只 QDII基金公告放宽限购额度，且部分场内ETF的溢价也有缓解之势。 作为QDII基金两大"去向"，港股与美股两大市场一直是投资焦点。半程行情落幕，港股QDII基金业绩大幅跑 赢美股相关产品，随着下半年行情开启，美股纳指、标普走出历史新高，港股当前估值仍然低于历史平均水 平，多家公募依旧旗帜鲜明地看好两大市场的投资前景。 多只QDII基金放宽限购额度 7月7日，易方达基金公告批量发布调整大额申购业务限制公告，调整旗下易方达标普医疗保健LOF、易方达信 息科技LOF、易方达生物科技LOF、易方达标普500LOF、易方达纳斯达克100ETF联接5只QDII的大额申购上 限。其中易方达纳斯达克100ETF联接单日申购上限从100元人民币调整至2000元，其余4只从100元调整至1000 元。 此外，近日华宝基金发布公告称，华宝致远混合型基金(QDII)将大额申购门槛由2万元调整为20万元，华宝纳 斯达克精选股票发起式(QDII)将大额申购门槛由5000元调整为2万元，华宝海外科技股票(QDII-LOF)将大额申 购门槛 ...